• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 5. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Phenylpiperidines

Introduction to 6-(Piperidin-4-yl)quinoline (CAS No. 1020277-40-0)

6-(Piperidin-4-yl)quinoline, with the CAS number 1020277-40-0, is a compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique molecular structure, which combines a quinoline core with a piperidine moiety. The quinoline ring is a well-known heterocyclic aromatic compound, widely used in the development of various pharmaceutical agents due to its diverse biological activities. The piperidine group, on the other hand, is a six-membered nitrogen-containing ring that is often found in bioactive molecules, contributing to their pharmacological properties.

The synthesis of 6-(Piperidin-4-yl)quinoline has been extensively studied, and several methods have been reported in the literature. One common approach involves the reaction of 6-chloroquinoline with piperidine under appropriate conditions. This method typically yields high purity and good yields, making it suitable for both laboratory-scale synthesis and potential industrial production. The versatility of this synthetic route allows for the introduction of various substituents on the quinoline and piperidine rings, thereby expanding the scope of potential applications.

In terms of its biological activities, 6-(Piperidin-4-yl)quinoline has shown promising results in multiple areas. Recent studies have highlighted its potential as an anti-inflammatory agent. In vitro experiments have demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6 in activated immune cells. This property makes it a potential candidate for the treatment of inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

Furthermore, 6-(Piperidin-4-yl)quinoline has been investigated for its anti-cancer properties. Research has shown that it can induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action appears to involve the modulation of key signaling pathways such as PI3K/Akt and MAPK, which are frequently dysregulated in cancer cells. These findings suggest that 6-(Piperidin-4-yl)quinoline could be developed into a novel therapeutic agent for cancer treatment.

The pharmacokinetic properties of 6-(Piperidin-4-yl)quinoline have also been studied to assess its suitability as a drug candidate. Preliminary data indicate that it has favorable absorption, distribution, metabolism, and excretion (ADME) profiles. It exhibits good oral bioavailability and a reasonable half-life, which are important considerations for drug development. Additionally, toxicity studies have shown that it is well-tolerated at therapeutic doses, with no significant adverse effects observed in animal models.

In the context of drug discovery and development, 6-(Piperidin-4-yl)quinoline represents an exciting lead compound with multifaceted biological activities. Its anti-inflammatory and anti-cancer properties make it a valuable candidate for further preclinical and clinical evaluation. Ongoing research is focused on optimizing its structure to enhance its potency and selectivity while minimizing potential side effects.

The future prospects for 6-(Piperidin-4-yl)quinoline are promising. As more data become available from preclinical studies and clinical trials, it is likely that this compound will play a significant role in the development of new therapeutic strategies for various diseases. The combination of its unique chemical structure and diverse biological activities positions it as a key player in the field of medicinal chemistry.

• 383861-22-1(5-(Piperidin-4-yl)-1H-indole)
• 914223-10-2(6-(piperidin-4-yl)-1H-indole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)